MB, BS (Hons), MD, FRACP, FRCPA
Consultant Haematologist
Head, Lymphoma Service, Alfred Hospital and Professor of Haematology, Monash University

Prof Tam has a keen interest in the biology and treatment of CLL and low-grade lymphoproliferative diseases. Prof Tam has extensive experience in the conduct of clinical trials, particularly those involving targeted therapies in B-cell malignancies.

He is the global lead for the novel BTK inhibitor BGB-3111, and he completed the first study in the world to combine ibrutinib and venetoclax (published in New England Journal of Medicine in 2018).

Prof Tam participates actively in peer-review and is on the editorial board of Blood Advances and Leukemia & Lymphoma. Since 2012, he has received over $14 million in grants. He has authored 149 papers, for a total of 3896 Web of ScienceTM citations. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, the American Association for Cancer Research, and the European Hematology Association.

Subspecialty interests include: CLL; HAIRY CELL LEUKEMIA; NON-HODGKIN LYMPHOMA; HODGKIN DISEASE